Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,468 total articles
IAU (iShares Gold Trust) is a liquid, low-cost proxy for the gold spot price. With a market cap of roughly $63.8B, solid daily liquidity and continued tailwinds for gold from central bank buying and easing rate expectations, this is a tactical long setup. Enter on weakness at $80.30, stop at $76.00, target $95.00 on a mid-term horizon (45 trading d…
Onto Innovation is poised to convert R&D and strategic investments into higher ASPs and better mix, unlocking upside to margins and free cash flow. With a market cap near $12B and trailing P/E north of 80, the stock already prices growth — the trade is that near-term weakness sets up a favorable entry ahead of product-driven margin improvement over…
<p>Ørsted remains one of the best-positioned pure-play offshore wind developers. With a deep pipeline, long-dated contracted cash flows and operating experience, the company is a sensible incremental buy here. This trade idea lays out an entry, stop and target for investors looking to add to a long position over the next 180 trading days while mana…
Telix looks like a high-upside trade after recent regulatory and clinical progress: a commercial win for Pixclara (FDA approval) combined with FDA alignment to advance TLX591-Tx into Part 2 of its ProstACT Global Phase 3 trial. Q2 revenue of $247M and Precision Medicine revenue of $202M underpin a business with real cash flows, while market cap sit…
Kinder Morgan (KMI) is positioned to benefit from stronger natural gas flows driven by LNG exports, power generation and new demand from AI data centers. The company combines low leverage, recurring take-or-pay contracts and a big project backlog. This trade idea recommends a swing-long entry at $30.50 with a $29.00 stop and a $33.50 target over a …
Nano Labs (NA) is trading at $2.35 with a market cap of roughly $54.2M after a steep operational drawdown in H1 2026. The business is pivoting toward AI + Web3 infrastructure while holding a strategic reserve of 70,000 BNB. Given cheap valuation metrics (PB ~0.84), technical improvement and meaningful insider conviction, we are upgrading to Buy and…
Freshworks ($FRSH) looks mispriced relative to its improving fundamentals. The company is generating meaningful free cash flow ($233.8M) and reported GAAP earnings per share of $0.71, yet the stock trades at only about $3.33B market cap and a mid-teens P/E. If management demonstrates sustainable GAAP profitability over the next two quarters and lev…
GameStop's cash balance and recent insider purchases have propped up the stock. But the underlying retail economics that made GameStop a mall staple are eroding as console makers go all-digital and second‑hand disc flows dry up. With a market cap near $11B and free cash flow under $600M, the stock looks vulnerable. This is a mid-term tactical short…
Birkenstock (BIRK) is trading close to its 52-week low despite mid-teens constant-currency growth targets, recent buyback programs and a lower leverage profile. Technically oversold and trading at a modest 14x trailing P/E with a $5.38B market cap, the stock offers an asymmetric risk/reward for a 45-trading-day swing anchored to $30.27 entry, $38.0…
Ascendis (ASND) is trading below its near-term moving averages after a strong run. Recent FDA approval of YUVIWEL for pediatric achondroplasia, a $400 million share-repurchase program and a settlement that turns a competitor into a royalty recipient materially change the company’s commercial and capital-allocation picture. We like the risk-reward f…
Energy Transfer (ET) is trading near its 52-week high with a 6.3% yield, roughly $72.4B market cap and free cash flow north of $5.2B. The business is toll-like, has 2.3x distribution coverage and room for modest distribution growth. For income-oriented traders who tolerate midstream cyclicality, the trade is to add on strength at ATHs, hold into fu…
AgomAb (AGMB) is a clinical-stage biotech targeting fibrosis with two lead programs: an inhaled ALK5 inhibitor (AGMB-447) for IPF and ontunisertib for fibrostenosing Crohn's disease. The company enters a catalyst-rich window with expected H2 2026 readouts and a patent protecting AGMB-447 through at least 2041. Balance sheet strength following the F…
Ameren trades near $103 and offers a mix of steady regulated cash flow, a 2.8% yield with 13 years of dividend increases, and transmission investments that should benefit from rising data center and enterprise demand for reliable, high-capacity power. Technicals look oversold and valuation is reasonable versus historical comfort for utilities. This…
Sandisk has already shown it can convert surging NAND prices and AI-driven demand into outsized profits and free cash flow. The market is discounting sustained earnings power. This trade targets a mid-term re-rating as steady datacenter and edge adoption translate into recurring revenue and strong cash generation.
Ondas looks like the rare high-growth defense/telecom equipment name where a single, strategic acquisition plus accelerating contract wins materially shorten the path to profitability. With a market cap near $4.08B, improving order flow, and an expected Cyberhawk close in Q3 2026, this trade buys a margin-recovery narrative at a reasonable entry an…
Tenable is turning AI interest into product-led revenue momentum. Recent wins - an OpenAI-powered AI inspector, FedRAMP High/IL5 authorization, and channel partnerships - give Tenable a credible path to reaccelerating growth. Trade idea: enter at current price, target $50 over a long-term (180 trading days) horizon, stop at $31 to limit downside if…
Applied Optoelectronics is trading well below its 2026 highs despite accelerating AI datacenter demand and an aggressive capacity expansion plan. Market cap sits near $8.3B while the business scales toward 800G/1.6T transceiver volumes. This trade idea targets a recovery leg that re-rates the company as execution proves out; entry $98.00, stop $80.…
Meta has shifted from platform upgrades to platform intelligence. With high-margin ad inventory, rising monetization levers across Facebook and Instagram, strong free cash flow and an improving AI product set, we see a clear path for re-rating. Entry $676.40, target $820, stop $600, long-term (180 trading days).
Broadcom is pulling back into technical support amid macro jitters. The business still prints exceptional free cash flow, commandingly high AI-relevant revenues and industry-leading margins. This trade idea targets a mid-term bounce to $380 with a clear stop at $320, using the pullback as a disciplined entry into a high-quality compounder.
Coherent (COHR) has retraced sharply from its 52-week highs and is now trading at an attractive entry point relative to near-term growth catalysts. Strong datacenter revenue growth, margin expansion, and clear capacity investments support a long-term trade. We upgrade to Buy and lay out an actionable entry, stop and target with a 180-trading-day ho…
Amazon is showing its best top-line acceleration in years, driven by a 37% AWS lift and 20% company revenue growth. Valuation is reasonable at ~20x earnings with room for re-rating if AWS continues to monetize AI infrastructure. This is a mid-term trade idea to buy the pullback with a clearly defined entry, stop and target.
Mirum Pharmaceuticals cleared near-term selling pressure and looks set for a mid-term rally as the market re-prices pipeline risk ahead of several commercial and clinical catalysts. The balance sheet, improving revenue trajectory and still-significant short interest create a favorable setup for a tactical long with defined risk control.
SITE shares have collapsed from a $168 52-week high to below $90. Fundamentals - a roughly $3.9B market cap, positive free cash flow of $259.3M, a modest debt load and a mid-20s P/E - argue the market is pricing in deeper structural troubles than the business shows. We present a trade idea to buy into a mid-term recovery driven by seasonal demand a…
SS&C Technologies ($80.64) looks attractively priced relative to its fundamentals. With $1.75B in free cash flow, an EV/EBITDA of 13.3 and a 52-week range of $61.40–$90.22, the market has overreacted to AI disintermediation headlines. This trade targets $95.00 over a long-term (180 trading days) horizon with a $72.00 stop loss—play a resilient soft…
Autoliv (ALV) is a durable supplier of airbags, seatbelts and active-safety components that combines cash generation, a healthy dividend, and a buyback-friendly balance sheet. Valuation looks reasonable at roughly $8.5B market cap and an EV/EBITDA of ~7.2. Technicals and elevated short activity increase near-term volatility, but a mid-term trade ca…
